Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 02/02/18 at 12:02pm

It's the first Friday of February, and it's time for another recap of the top ten articles most popular with our readers this week.

The United States' most foremost public health body, the Centers for Disease Control and Prevention, was shaken this week with the news that its Director has resigned after being discovered to have purchased stocks in big tobacco. And that's not the only resignation this week, after Apotex President and CEO Jeremy Desai leaves amidst allegations he accepted company secrets from Teva - just a month after the company's founder was found murdered.

Sanofi also made its second major acquisition of the year so far, buying out Ablynx for $4.8 billion, but the most popular story this week was the first tangible news of retail giant Amazon's much-talked-about foray into the healthcare industry.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Brexit Health Alliance warns of UK at back of the medicine queue

The Brexit Health Alliance has cautioned that unless a favourable deal is struck, the UK could end Brexit negotiations as a comparatively small patient population in a global market – putting the country to the back of the queue in bringing new medicines to its shores.

9. CDC Director resigns over tobacco stock scandal

Dr Brenda Fitzgerald, the Director of the Centers for Disease Control and Prevention, the United States’ leading national public health institute, has resigned from her post amidst controversy surrounding financial conflicts of interest.

8. New blood test for Alzheimer’s offers hope

A new test is able to use a small amount of blood to determine, with 90% accuracy, whether a patient had a build of amyloid protein in the brain.

7. Santhera's Raxone rejected in Europe for Duchenne muscular dystrophy

Santhera’s Raxone was left out of a recent raft of positive recommendations, rejected by an EMA advisory panel and given a negative opinion in the treatment of Duchenne muscular dystrophy (DMD).

6. Apotex President resigns amidst Founder's murder and allegations of accepting Teva secrets

Canada’s largest generic drug producer Apotex has now lost its President and CEO, as Jeremy Desai resigns effective immediately, to “pursue other opportunities.

5. AZ’s triple therapy inhaler hits 8 out of 9 endpoints

AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints in the treatment of moderate to very severe chronic obstructive pulmonary disease.

4. EMA committee recommends seven therapies from Roche, GSK, MSD and more

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of products in a number of therapeutic areas, including candidates from GlaxoSmithKline, Roche and MSD.

3. Sanofi swoops for Ablynx in $4.8bn deal

Sanofi has moved quickly to tie up a deal with Ablynx for $4.8 billion, when it looked more likely that Novo Nordisk would wear down the biotech’s resistance with repeated bids.

2. Italy refuses to give up hope on EMA HQ

It is no secret that Milan was not best pleased that it was pipped to the post to host the EMA headquarters by Amsterdam, and now it is attempting to get the decision revoked.

1. Amazon makes first steps into healthcare, alongside big partners

Amazon’s move into the healthcare sector has been widely mooted over the last 12 months and it officially announced that it would enter the space as part of a joint venture alongside Berkshire Hathaway and JPMorgan Chase.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches